Comparative Pharmacology
Head-to-head clinical analysis: INTRAROSA versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INTRAROSA versus LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL.
INTRAROSA vs LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Intrarosa (prasterone) is an exogenous dehydroepiandrosterone (DHEA) that is converted locally to androgens and estrogens, primarily testosterone and estradiol, in vaginal cells. It restores the hormonal environment of the vaginal tissue, improving epithelial integrity and reducing symptoms of vulvovaginal atrophy.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; levonorgestrel alters cervical mucus and endometrial lining to prevent fertilization and implantation.
6.5 mg administered intravaginally once daily at bedtime for 21 days.
One tablet containing 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol (or 0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo or ethinyl estradiol 0.01 mg alone. For extended-cycle regimens, dosing may be continuous for up to 84 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5 hours, allowing for twice-daily dosing in maintenance therapy.
Levonorgestrel: ~25 hours; Ethinyl estradiol: ~13 hours. Steady-state achieved within 5-7 days; clinical efficacy maintained by daily dosing.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; biliary/fecal elimination accounts for the remaining 40%, with minimal hepatic metabolism.
Levonorgestrel: 45% renal, 32% fecal; Ethinyl estradiol: 40% renal, 60% fecal. Both undergo enterohepatic recirculation.
Category C
Category D/X
Estrogen
Estrogen